Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.37 - $0.69 $17,982 - $33,534
48,600 New
48,600 $22,000

Others Institutions Holding EFTR

About eFFECTOR Therapeutics, Inc.


  • Ticker EFTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,452,800
  • Description
  • eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...
More about EFTR
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.